secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001628280-24-047433
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 reports positive Phase 2 mavorixafor data: ANC normalized, G-CSF reduced 70% in chronic neutropenia
--------------------------------------------------------------------------------

- Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).
- Severe CN patients achieved >2-fold mean ANC increase over 6 months (n=4).
- G-CSF dose reduced in 9/12 eligible patients; mean reduction 52% at Month 3, 70% at Month 6 with normal ANC.
- Neutrophil functionality sub-study: mean % functional neutrophils comparable to healthy donors after 6 months.
- No drug-related serious adverse events; mavorixafor generally well tolerated as monotherapy and combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/0001628280-24-047433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024047433/xfor-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer